Bass, Berry & Sims attorney Danielle Sloane spoke with a reporter from MedTech Dive for an article examining the Trump administration’s focus on fraud related to genetic testing. In 2025, as part of the National Health Care Fraud Takedown brought by the Department of Justice that resulted in criminal charges against 324 defendants representing $14.6 billion in intended losses, genetic testing and telemedicine fraud accounted for more than $1.17 billion in alleged fraudulent claims to Medicare.
“Those cases, in combination with the increase in spending, explains the focus on genetic testing,” said Danielle.
In late February, the Centers for Medicare and Medicaid Services (CMS) issued an RFI that in part asks for feedback on possible regulatory changes that would aim to prevent fraud in laboratory testing, such as molecular and genetic tests. The RFI asks specifically about expanded utilization of the Molecular Diagnostic Services program (MolDX), which is not currently followed in in every state.
“If there’s going to be expanded use of the MolDX program by Medicare, the government should provide consistency and oversight to make sure it is applied uniformly,” said Danielle.
The full article, “Genetic tests come under scrutiny in Trump administration’s fraud crackdown,” was published by MedTech Dive on March 12 and is available online. The article was republished by Healthcare Dive.